A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus. - Wikidata - wikimedia - TriplyDB

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.

http://www.wikidata.org/entity/Q35050662

about

Molecular-targeted therapy for advanced gastric cancer Molecular-targeted first-line therapy for advanced gastric cancer Role of nitric oxide in the pathogenesis of Barrett's-associated carcinogenesis Targeting receptor tyrosine kinases in gastric cancer The relation of EGFR expression by immunohistochemical staining and clinical response of combination treatment of nimotuzumab and chemotherapy in esophageal squamous cell carcinoma.The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma.Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers Translational research in thoracic surgery-the National Taiwan University Hospital experience A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus.Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform.An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of esophageal carcinoma and the suggested mechanisms of action Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.New and emerging combination therapies for esophageal cancer.Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies.Predictive value of EGFR overexpression and gene amplification on icotinib efficacy in patients with advanced esophageal squamous cell carcinoma.KRAS and BRAF mutations in 203 esophageal squamous cell carcinomas: pyrosequencing technology and literature review.Berberine inhibits EGFR signaling and enhances the antitumor effects of EGFR inhibitors in gastric cancer Targeted therapy in gastrointestinal malignancies.End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice.Targeted therapy for gastric cancer.Emerging tyrosine kinase inhibitors for esophageal cancer.Epidermal growth factor receptor: an important target in esophageal cancer.Investigational therapies targeting the ErbB family in oesophagogastric cancer.EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.Biomarkers and novel agents in esophago-gastric cancer: are we making progress?Novel EGFR-targeted strategy with hybrid peptide against oesophageal squamous cell carcinoma.Synergistic effect of targeting the epidermal growth factor receptor and hyaluronan synthesis in oesophageal squamous cell carcinoma cells.Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways.Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma.Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification.Targeted treatments for metastatic esophageal squamous cell cancer Expression, regulation and targeting of receptor tyrosine kinases in esophageal squamous cell carcinoma.Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis.Mouse avatar models of esophageal squamous cell carcinoma proved the potential for EGFR-TKI afatinib and uncovered Src family kinases involved in acquired resistance A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification

P2860

Q24187006-9E8A2E90-3E77-4725-9237-43A63FABE95E Q26471049-F4321A9E-D1D3-4823-868F-DC0848722674 Q26766641-06B15A9D-ABFD-4BBE-A943-D6802B294674 Q27013050-B16F2AAA-130F-4216-93AE-0F9D172FA2F8 Q27853223-33F34BCE-870E-40D0-8363-5D41B0315A23 Q27853383-C693945F-7AE8-4E00-84E9-3199BF02DDD8 Q28066550-0C10AEEF-B109-4653-853A-DD82BC0ED4AC Q28073690-29D4281D-D72A-42F1-92C3-F683F49D663F Q33405628-A8B411B1-645E-49C0-9DD7-817B2612514F Q33903687-3A2A8EA3-9701-4450-8169-4F76F58DDB01 Q35130286-80D94305-5834-4A18-80B8-188381370A58 Q36475391-E0D48794-1139-4CA0-8F61-F81EEF48369D Q36689140-53EEC599-548E-43A7-AA1A-4EEC0471F99B Q36996728-CA3D11F4-0EE4-4841-8A76-CE6BB480723C Q37038482-F1320D3C-F230-4C7C-BB5E-EE6ECEE17085 Q37269426-CF9B71D5-E9AF-42E7-A5E5-CB567948A19B Q37369576-9EE46C13-234A-4103-A1CE-CEF8F651385F Q37689064-3C12BEB2-DE1F-4B23-B541-651C3CB45773 Q37702506-52CA2D9A-D5AC-402F-9895-0E11C98B1EF9 Q37921009-CDA4A979-3365-46A2-B1BC-322E1FA6F451 Q38007119-A328639B-F145-419B-A5D3-A83B5BC241D2 Q38110962-CB973A06-7F22-4B75-9CE3-F0FFF03EDA06 Q38121640-A4E846D0-A2FC-4125-BB9C-DCC27680F064 Q38221886-86A8B920-DE49-4EE0-BEF3-779BFDE3E6B0 Q38392935-BB2A111B-4732-4368-A131-5366C4382B55 Q38575013-18A0FD6B-0564-4B59-AF99-0F8338AE14F9 Q38787773-02459200-B8BE-4CF6-AFD0-10E0BF01579E Q38856978-E150221A-5DEB-4E78-A118-1DEB4B52CA86 Q38939088-828DC3CD-124C-49C8-B459-F7BE9855BFF5 Q38968846-F38DBC62-D470-4794-AB13-26C02E62BF9E Q38970911-0A604A66-D9D7-470D-A3F4-E45DF36D8A09 Q39636368-512470E7-576A-4BF3-8F85-5A69FE57BB4E Q41612476-FA0FA205-27FD-4B39-843B-454C7F547508 Q42154615-5DAE973D-72AB-446A-A76C-1F8FF5730291 Q49887971-D4EBD06A-20AE-45E4-B529-BD93CCAF1384 Q54501808-7E5C18EB-0443-42CD-9223-B0A7805036BB Q58696689-32E221E3-5AD3-40D3-8E4F-8F24A1A3C170 Q58771181-53176B5D-53DC-4EAA-8016-15569F53DE14

P2860

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.

http://www.wikidata.org/entity/Q35050662

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A phase 2 trial of erlotinib i ...... enocarcinoma of the esophagus.

@ast

A phase 2 trial of erlotinib i ...... enocarcinoma of the esophagus.

@en

type

label

A phase 2 trial of erlotinib i ...... enocarcinoma of the esophagus.

@ast

A phase 2 trial of erlotinib i ...... enocarcinoma of the esophagus.

@en

prefLabel

A phase 2 trial of erlotinib i ...... enocarcinoma of the esophagus.

@ast

A phase 2 trial of erlotinib i ...... enocarcinoma of the esophagus.

@en

P1433

Q35050662-ADAAF86F-A167-4B65-BB23-B35FD85ABDA7

P1476

Q35050662-05F47459-A978-4E5B-A90F-51F01460FAD3

P2093

Q35050662-1692041C-5233-402F-AD5B-C91C9760F304

Q35050662-5011FE18-0747-447E-89A0-48D6B2AB5457

Q35050662-535230CE-23F2-45F7-AC69-DB71CD063543

Q35050662-7D526A38-7F1E-4333-8AEE-726B5BD12C75

Q35050662-8B9135BA-F385-4B41-93C3-8085148EE61B

Q35050662-9B5BEEFE-DFB2-48E4-A4FA-C9EF140BADA8

Q35050662-B1558F8B-F98F-47C0-962E-5289BF1EF534

Q35050662-B28C1E9E-F019-4F17-993D-9D08AE4AC4AC

Q35050662-DB80BCEA-7587-4F04-8F84-B0625581C816

P2860

Q35050662-0E020856-9737-4267-8145-32345BC0036F

Q35050662-15FEB0EC-DE34-4F27-83A9-E09DCE177CAE

Q35050662-17B42F88-A62D-4199-9382-CCD6E4540DE2

Q35050662-18771BC3-2907-4EBD-9234-3E8A3EDF34D5

Q35050662-401497E3-B71C-4511-B9A1-CF80C9E7B5D7

Q35050662-5A472BCA-F434-4709-A3B4-813E9056EDEB

Q35050662-626845FF-1469-4E06-AEFF-4A59EF663685

Q35050662-6ED2FF5F-1DD9-4013-AE21-C4A505D1FCBB

Q35050662-7BF75A68-913F-498D-BEC6-EDB22725AAFF

Q35050662-85A1DB6A-2063-4C54-A4AA-7541E4C70391

P304

Q35050662-A2E8DB04-7B8B-421A-B120-83471A8DFDF5

P31

Q35050662-3DE1B8F5-8247-403A-9AC1-FEAD921C30A3

P356

Q35050662-6537986A-0601-41F2-A127-1051B453B48F

P407

Q35050662-5458A3FA-6149-4F62-8D95-40948B39A061

P433

Q35050662-7AB1B713-AD78-46FD-8280-07E2D950DA6B

P478

Q35050662-C9828E10-CB75-4E57-851C-08BE6D7F88DC

P577

Q35050662-58090F26-EB0C-47B4-A08E-DD00E08E420E

P5875

Q35050662-D9715E4C-39C1-4A16-93AA-499E7CDEBD77

P698

Q35050662-0BCCC92C-FA56-484B-8D2D-803AE1AC56BE

P921

Q35050662-3608BADE-7E18-4D7D-B5CF-DA01ED161AE6

Q35050662-EC0DC439-668F-48B7-A96C-950F766431B4

P932

Q35050662-33493CF7-25D7-4DB5-9C77-FCD9BCC91A74

P356

P1433

P1476

A phase 2 trial of erlotinib i ...... enocarcinoma of the esophagus.

@en

P2093

Benjamin Miron

http://www.w3.org/2001/XMLSchema#string

David H Ilson

http://www.w3.org/2001/XMLSchema#string

David Kelsen

http://www.w3.org/2001/XMLSchema#string

David Klimstra

http://www.w3.org/2001/XMLSchema#string

Douglas A Levine

http://www.w3.org/2001/XMLSchema#string

Gary Schwartz

http://www.w3.org/2001/XMLSchema#string

Jeff Boyd

http://www.w3.org/2001/XMLSchema#string

Manish Shah

http://www.w3.org/2001/XMLSchema#string

Marinela Capanu

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Epidemiology and pathogenesis of esophageal cancer

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

The changing epidemiology of esophageal cancer.

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.

Esophageal cancer: adjuvant therapy.

P304

1409-1414

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.25602

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2010-11-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50598527

http://www.w3.org/2001/XMLSchema#string

P698

21425140

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3116987

http://www.w3.org/2001/XMLSchema#string